Article, 2024

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

Pharmaceutical Research, ISSN 0724-8741, 1573-904X, Volume 41, 4, Pages 711-720, 10.1007/s11095-024-03693-3

Contributors

Brigitha, Leiah J 0000-0003-2816-2610 [1] [2] Mondelaers, Veerle [3] [4] Liu, Yiwei [5] Albertsen, Birgitte Klug 0000-0002-3902-3694 [6] Zalewska-Szewczyk, Beata [7] Rizzari, Carmelo 0000-0002-4828-3893 [8] [9] Kotecha, Rishi Sury 0000-0003-1836-4075 [10] [11] [12] Pieters, Rob [2] Huitema, Alwin D. R. [2] [13] [14] [15] Van Der Sluis, Inge M 0000-0002-5822-7668 (Corresponding author) [2]

Affiliations

  1. [1] Erasmus MC - Sophia Children’s Hospital
    2. [NORA names: Netherlands; Europe, EU; OECD];
  2. [2] Princess Máxima Center
    3. [NORA names: Netherlands; Europe, EU; OECD];
  3. [3] Ghent University
    4. [NORA names: Belgium; Europe, EU; OECD];
  4. [4] Ghent University Hospital
    5. [NORA names: Belgium; Europe, EU; OECD];
  5. [5] The University of Texas MD Anderson Cancer Center
    6. [NORA names: United States; America, North; OECD];

Abstract

BackgroundPEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population.MethodsInfants with ALL who received treatment with PEGasparaginase were included in our population pharmacokinetic assessment employing non-linear mixed effects modelling (NONMEM).Results68 infants with ALL, with a total of 388 asparaginase activity samples, were included. PEGasparaginase doses ranging from 400 to 3,663 IU/m2 were administered either intravenously or intramuscularly. A one-compartment model with time-dependent clearance, modeled using a transit model, provided the best fit to the data. Body weight was significantly correlated with clearance and volume of distribution. The final model estimated a half-life of 11.7 days just after administration, which decreased to 1.8 days 14 days after administration. Clearance was 19.5% lower during the post-induction treatment phase compared to induction.ConclusionThe pharmacokinetics of PEGasparaginase in infants diagnosed under one year of age with ALL is comparable to that of older children (1–18 years). We recommend a PEGasparaginase dosing at 1,500 IU/m2 for infants without dose adaptations according to age, and implementing therapeutic drug monitoring as standard practice.

Keywords

ConclusionThe, ConclusionThe pharmacokinetics, MethodsInfants, PEGasparaginase, active sampling, acute lymphoblastic leukemia, adaptation, administration, age, asparaginase, assessment, body, body weight, children, clearance, data, days, diagnosed ALL, diagnosis, distribution, dose, dose adaptation, drug, drug monitoring, effects model, evidence, half-life, implementing therapeutic drug monitoring, induction, infants, insufficient evidence, international studies, leukemia, lymphoblastic leukemia, mixed effects models, model, monitoring, non-linear mixed effects model, older children, one-compartment model, optimal dose, pediatric acute lymphoblastic leukemia, pharmacokinetic assessment, pharmacokinetics, phase, population, practice, samples, standard practice, study, therapeutic drug monitoring, time-dependent clearance, transition, transition model, treating pediatric acute lymphoblastic leukemia, treatment, treatment phase, volume, volume of distribution, weight, years, years of age

Funders

  • Vlaamse Liga tegen Kanker

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+